--- title: GE HealthCare (GEHC) — intrinsic value and fair price canonical: https://sweetvaluelab.com/stocks/gehc ticker: GEHC as_of: 2026-10-18 sector: Healthcare industry: Medical - Devices --- # GE HealthCare (GEHC) GE HealthCare (GEHC) closed at $69.57 on Oct 16, 2026, undervalued by 40% vs its model value of $115.43 (from a five-year discounted cash flow). ## Key figures | Figure | Value | | --- | ---: | | Last close | $69.57 (Oct 16, 2026) | | Model value (from a five-year discounted cash flow) | $115.43 | | Price vs model | undervalued by 40% vs model | | Range of that model | $68.18 – $339.47 | | Market value | $31.4B | | P/E (fiscal 2025) | 15.3 | | Net margin (fiscal 2025) | 10.1% | | Free cash flow (fiscal 2025) | $1.5B | | Dividend yield (trailing twelve months) | 0.20% | | Beta | 0.85 | | Cost of capital (WACC) | 7.59% | | Business classification | Mature & Stable (Low/slowing growth (~3% recent), Moderate margins (10% net margin)) | ## Dividends | Figure | Value | | --- | ---: | | Trailing dividend yield | 0.20% | | Dividends per share, last 12 months | $0.14 | | Dividends / free cash flow (fiscal 2025) | 4.3% | | Raised | 1 years in a row | | Growth over 2 years | 8.0% a year | | Latest payment | $0.035, ex-date Jul 24, 2026, paid Aug 14, 2026 | | Year of payments | Dividends per share | | --- | ---: | | To Jul 19, 2024 | $0.12 | | To Jul 25, 2025 | $0.14 | | Trailing twelve months (to Jul 24, 2026) | $0.14 | ## Valuation models Each model's value per share and the role the engine gave it for this business. The headline above is one model's value; every other model is listed with its own, and each has a page of its own under the valuation. Computed Oct 18, 2026. | Model | Role | Value per share | Low | High | | --- | --- | ---: | ---: | ---: | | DCF · Perpetuity growth · 5y | primary | $115.43 | $68.18 | $339.47 | | DCF · Perpetuity growth · 10y | cross check | $121.94 | $74.57 | $343.10 | | DCF · EBITDA exit · 5y | cross check | $113.73 | $78.99 | $154.66 | | DCF · EBITDA exit · 10y | cross check | $120.52 | $82.96 | $170.58 | | P/E · peers | cross check | $93.09 | $85.84 | $104.65 | | P/E · own history | cross check | $84.92 | $76.72 | $116.24 | | PEG | sanity check | $49.83 | $49.83 | $49.83 | | EV/EBITDA · peers | cross check | $96.73 | $69.93 | $99.16 | | EV/Revenue · peers | cross check | $157.40 | $108.14 | $162.35 | | Earnings power value | cross check | $0.00 | $0.00 | $0.00 | | Dividend discount | cross check | $4.10 | $2.78 | $6.36 | ## Insider activity (SEC Form 4) No open-market insider buys or sales filed in the past 90 days. | Date | Insider | Relationship | Transaction | Shares | Value | | --- | --- | --- | --- | ---: | ---: | | Sep 14, 2026 | Grogan William K | Chief Financial Officer | Grant / award | 62,256 | $0 | | Sep 14, 2026 | Grogan William K | Chief Financial Officer | Grant / award | 12,840 | $0 | | Sep 14, 2026 | Grogan William K | Chief Financial Officer | Grant / award | 31,877 | $0 | | Sep 3, 2026 | Rackliffe Philip | CEO, AIS | Tax withholding | 798 | $56,306.9 | | Sep 3, 2026 | O'Neill Kevin Michael | CEO, PDx | Tax withholding | 718 | $50,662.1 | ## Recent SEC filings | Filed | Form | What | Filing | | --- | --- | --- | --- | | Sep 22, 2026 | 8-K | 5.02 Departure/Election of Directors or Officers; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/1932393/000193239326000053/gehc-20260922.htm | | Aug 18, 2026 | 8-K | 5.02 Departure/Election of Directors or Officers; 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/1932393/000193239326000050/gehc-20260813.htm | | Jul 29, 2026 | 8-K | 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/1932393/000193239326000047/gehc-20260729.htm | | Jul 29, 2026 | 10-Q | Quarterly report | https://www.sec.gov/Archives/edgar/data/1932393/000193239326000046/gehc-20260630.htm | | Jul 29, 2026 | 8-K | 2.02 Results of Operations (Earnings); 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/1932393/000193239326000045/gehc-20260729.htm | ## Superinvestors holding it (latest 13F) | Manager | Quarter | Shares | Value | | --- | --- | ---: | ---: | | Dodge & Cox | 2026-06-30 | 37,864,164 | $2.4B | | Bill Nygren | 2026-06-30 | 15,329,664 | $981.3M | | Nelson Peltz | 2026-06-30 | 3,085,344 | $197.5M | | Leon Cooperman | 2026-06-30 | 1,309,500 | $83.8M | 9 tracked managers in all. ## About GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health prod… --- Source: https://sweetvaluelab.com/stocks/gehc (SweetValueLab, free, no account). Prices and statements from Financial Modeling Prep; filings from SEC EDGAR. Research and educational data, not investment advice; nothing here is a recommendation to buy, sell or hold any security.